Intellia Therapeutics, Inc. — Form 8-K
Filed November 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Intellia's lonvoguran ziclumeran (lonvo-z), an in vivo CRISPR gene therapy for hereditary angioedema (HAE), achieved its Phase 3 HAELO primary endpoint: 62% mean attack-rate reduction weeks 5–28 versus placebo (p<0.0001); 87% of patients attack-free weeks 5–28 (p<0.0001). FDA accepted the BLA on September 3, 2026, with priority review granted and PDUFA goal date of March 10, 2027. No advisory committee planned. Across 117 patients in integrated Phase 1/2/3 analysis (up to 4 years follow-up), lonvo-z showed durable kallikrein reduction, 100% of patients remain LTP-free, and favorable safety (2 Grade 3 SAEs unrelated to drug).
Why this rating
First-in-class one-time CRISPR therapy for HAE with strong efficacy/durability data; BLA accepted with priority review. Clinical validation de-risks launch for ~$870M company; material near-term revenue catalyst if approved March 2027.
Tradability signal
NO TRADE
No trade: positive news with only -2.2% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.36% over 4 hrs, n=469). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $10.60 ▲ 1.53% | at our read · unknown $10.44 | +10 min · unknown $10.30 ▼ 1.29% | +30 min · unknown $10.19 ▼ 2.39% | +1 hr · unknown $10.15 ▼ 2.78% | +4 hrs · unknown $10.34 ▼ 0.96% |
The stock had already moved -1.51% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.